Thanks CBS!
Eric had asked the following:
Does anyone know if the Bannert group could not find any XMRV at all? Or did they find the ~3% that would have to be there? If they couldn't find any, i think it's pretty safe to assume that they have used a different method compared to this latest study or did not work properly.
OK eric, here's what I found from the Bannert/Hohn paper provided by CBS:
Xenotropic Murine Leukemia Virus–related Gammaretrovirus in Respiratory Tract In total, 146 sera from prostate cancer patients and 5 healthy control individuals were tested negative for antibodies binding recombinant XMRV gp70 and Gag proteins in ELISA, although postive control immunized mouse sera reacted strongly (Fig. 5A and 5B). One patient serum that reacted strongly in ELISA against the recombinant pr65 protein was subsequently tested by immunofluorescence assay using HEK 293T cells expressing XMRV and cells expressing the gp70- or pr65 proteins alone. No XMRV specific binding was seen, indicating a non-specific ELISA reaction.
…As additional controls we tested the cell lines 22Rv1 (XMRV positive [17]) and DU145 (XMRV negative [9]). As expected, 22Rv1 was found to be strongly positive for RNA transcripts and for provirus (with In-For/Deletion-Rev primers), while DU145 was negative in both PCR approaches (data not shown).
From Figure 2: Nested-PCR screen of the first 16 QQ patients (lane 1-16) with the In-For and Deletion-Rev primer pair (upper panel) and In-For and In-Rev primer setup (lower panel); lane 17 = mouse tail DNA, lane 18 = water control outer PCR mix, lane 19 = water control inner PCR mix, lane 20 = pXMRV, lane 21 = pDG75, marker = 100 bp marker.In other words, the original Hohn/Bannert paper used water as a negative control, as well as cell line DU145 (XMRV negative). And they also tested "5 healthy control individuals".
Based on these low control numbers of actual humans, it would be impossible to determine prevalence in controls for comparison.
But did Hohn/Bannert in the original negative prostate paper use the same methods as Hohn did in his positive respiratory secretions paper????
Anyone??
Hi Parvo
Once again, this seems to be a situation, where it's very hard to make sense of the information we hear. Since the XMRV story started to make news, i try to figure out what's going on and just can't reach a conclusion. It seems when it's about CFS the world does not work in any logical way.
Thanks a lot for your answers, here's what i think:
In the original Bannert study
"Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients" he seems to have found 0 cases of XMRV infection. If i read your information correctly.
But as we can now see from
"Xenotropic Murine Leukemia Virus-related Gammaretrovirus in Respiratory Tract" there seems to be a prevalence of XMRV in German healthy controls, people with RTI and people with RTI who have had transplantation. This is consistent with the Science study and the Japanese Red Cross values and so i think it's likely that those results are correct.
For that reason, i think that at least in
"Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients" they have used a different method or did not apply their method correctly, because i don't see any reason why those German prostate cancer patients should all be XMRV negative, if XMRV is around in Germany and can be found in different groups of the population.
We can't say about the Bannert CFS study discussed in Prague because we don't know yet if they have found 0 cases there or if they have found some percentage to be positive.
Now what confuses me is this:
How long did the work on
"Xenotropic Murine Leukemia Virus-related Gammaretrovirus in Respiratory Tract" take? It must have overlapped at least with the latest CFS study. Right?
I can hardly believe that Hohn is involved in all of those studies and while they can find XMRV in one study, as is to be expected at least in some one digit percentage of cases, he will not tell the Bannert group and they go on to publish a study where they couldn't find any.
So it would be very interesting to see what they have found in that study that they talked about in Prague. Because that one was only finished recently. So far i'm only sure that they did not find a high prevalence.
Nina said:
Next thing we know, Bannert's team present their findings at the Prague conference and say they still haven't found XMRV in CFS patients.
If that means they have not found any case of infection, then i don't understand what's going on. It could only mean that Hohn did not tell them about the other study's finding, that there they could find it, or that they just did not listen to him (not very intelligent) or that it was too late to not publish it. [Edit: Another possibility would be that the study only looked at such a small number of people that it would not pick up an ~5% prevalence, with some bad luck during the selection. I think now i can remember that it only involved 20 to 30 persons. But i'm not sure at all about that number.]
I really think all we can do is to either ask those people, which would be great if they answer, but i'm not too confident they will, or then to just wait for another study by them. I'm not German and i think the RKI and Charit are very good but i don't think it's their culture to answer emails from people outside of the scientific community (i mean not employed by a scientific institution) who they don't know. Probably that's much more common in America.
Ciao
Eric